What is the appropriate dosing regimen for guanfacine (including immediate‑release and extended‑release formulations) in adults and children, and how should the dose be adjusted in hepatic impairment?

Guanfacine Dosing

For children and adolescents with ADHD, guanfacine extended-release should be dosed at 0.1 mg/kg once daily, starting at 1 mg and titrating weekly by 1 mg increments to a maximum of 4 mg based on body weight and tolerability. 1

Dosing Regimen by Formulation

Extended-Release Guanfacine (Primary ADHD Formulation)

Children and Adolescents (6-17 years):

• Starting dose: 1 mg once daily (preferably at bedtime to minimize somnolence)
• Titration: Increase by 1 mg weekly as tolerated
• Target dose: 0.1 mg/kg/day (rule of thumb) 1
• Maximum dose: 4 mg/day (FDA-approved ceiling) 2
• Available strengths: 1,2,3, and 4 mg tablets 1

Weight-adjusted dosing considerations: Evidence suggests doses >0.08 mg/kg but ≤0.12 mg/kg may provide additional clinical benefits if tolerated 3. For many adolescents, particularly those >70 kg, this would exceed the 4 mg FDA-approved maximum, though higher doses up to 9 mg have been studied in adolescents aged 13-17 years with acceptable safety profiles 3.

Adults:

• Extended-release guanfacine is not FDA-approved for adults with ADHD
• Limited data exists; one study showed 4 mg ER daily achieved similar plasma levels to 3 mg immediate-release in adult smokers 4

Immediate-Release Guanfacine (Hypertension Formulation)

Adults (hypertension only):

• Starting dose: 1 mg once daily at bedtime
• Titration: May increase to 2 mg after 3-4 weeks, then to 3 mg if needed
• Usual maintenance: 1-3 mg once daily
• Maximum: 3 mg/day 5

Critical warning: Immediate-release and extended-release formulations are NOT interchangeable on a mg-for-mg basis due to different pharmacokinetics 2. A case report documented severe bradycardia and hypotension requiring ICU admission when a 6-year-old received 2 mg immediate-release instead of 2 mg extended-release 6.

Dose Adjustments in Hepatic Impairment

The FDA label does not provide specific hepatic dosing adjustments 5. However, guanfacine is primarily metabolized via CYP3A4 and excreted predominantly renally (approximately 50% unchanged in urine) 1, 5.

Practical approach:

• Mild-to-moderate hepatic impairment: Start at the low end of the dosing range and titrate cautiously
• Severe hepatic impairment: Use with extreme caution; consider alternative agents
• The drug is approximately 70% protein-bound, which may be altered in hepatic dysfunction 5

Renal Impairment Considerations

While not specifically asked, this is clinically relevant: Guanfacine clearance is reduced in renal insufficiency, but plasma levels increase only slightly 5. Start at the low end of the dosing range in renal impairment. The drug is poorly dialyzed, so usual doses can be given to dialysis patients 5.

Pharmacokinetic Profile

• Time to peak: 1-4 hours (average 2.6 hours) 5
• Half-life: 17 hours average (range 10-30 hours); younger patients 13-14 hours, older patients up to 30 hours 5
• Steady state: Achieved within 4 days 5
• Bioavailability: Approximately 80% 5
• Onset of therapeutic effect: 2-4 weeks for ADHD symptoms 1

Critical Safety Considerations

Cardiovascular monitoring is mandatory:

• Measure heart rate and blood pressure at baseline, after dose increases, and periodically during maintenance 7
• Guanfacine causes dose-dependent decreases in heart rate (average 5 bpm) and blood pressure 5, 3
• The physiologic response of increased BP upon standing is blunted in a dose-related manner 3
• Obtain personal and family cardiac history; perform ECG if risk factors present 7

Discontinuation:

• Never stop abruptly - taper gradually to avoid rebound hypertension 1, 7
• Guanfacine withdrawal produces more gradual blood pressure increases than clonidine, but occasional values significantly exceeding baseline can still occur 5

Most common adverse effects (dose-related, typically transient):

• Somnolence (38.6% in trials) 8
• Headache (20.5%) 8
• Fatigue (15.2%) 8
• Irritability, dizziness, abdominal pain 1, 9

These effects typically emerge within the first 2 weeks and generally resolve by study end without interfering with attention improvements 9.

Clinical Context

Guanfacine is considered second-line therapy for ADHD, with stimulants remaining first-line due to larger effect sizes 1. In Europe, guanfacine is only approved when stimulants are unsuitable, not tolerated, or ineffective 1. Extended-release guanfacine and clonidine are the only medications with FDA approval as adjunctive therapy to stimulants 7.